Can a pregnant woman safely take fluoxetine and aripiprazole?

Can Fluoxetine and Aripiprazole Be Taken During Pregnancy?

Both fluoxetine and aripiprazole can be used during pregnancy when clinically necessary, but require careful risk-benefit assessment, with fluoxetine having more reassuring long-term safety data than aripiprazole.

Fluoxetine in Pregnancy

Safety Profile

Fluoxetine does not increase the risk of major congenital malformations or spontaneous pregnancy loss 1, 2. Large observational studies demonstrate that associations between prenatal SSRI exposure (including fluoxetine) and neurodevelopmental problems like autism spectrum disorder and ADHD are largely due to confounding factors rather than the medication itself 3.

Key Considerations

• First and second trimester exposure: Generally well-tolerated with no increased risk of major structural anomalies (5.5% vs 4.0% in controls) 1
• Third trimester exposure: Associated with increased risk of:
  • Premature delivery (relative risk 4.8)
  • Special-care nursery admission (relative risk 2.6)
  • Poor neonatal adaptation including respiratory difficulty, cyanosis, and jitteriness (relative risk 8.7)
  • Lower birth weight and shorter birth length 1

Clinical Approach

The evidence suggests that untreated maternal depression poses significant risks including increased relapse, hospitalization, suicide risk, and adverse perinatal outcomes 3. Women who discontinue antidepressants during pregnancy experience higher relapse rates than those who continue treatment 4.

For women with moderate-to-severe depression or history of severe episodes requiring fluoxetine, continuing treatment is generally justified as the benefits outweigh the risks 3.

Aripiprazole in Pregnancy

FDA Labeling and Registry

The FDA drug label indicates that neonates exposed to antipsychotics including aripiprazole during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder) 4. A pregnancy exposure registry exists (1-866-961-2388).

Available Safety Data

• No established increased risk of major birth defects based on published epidemiologic studies 4
• Animal studies showed developmental toxicity at doses 10 times the maximum recommended human dose, including delayed fetal development and undescended testes 4
• Limited human data from retrospective studies (26 women in one study) suggest:
  • No increased gestational diabetes risk
  • Possible increased pregnancy hypertension
  • Lower birth weight and shorter gestation
  • Higher neonatal admission rates 5

Evidence Quality

The data for aripiprazole is considerably more limited than for fluoxetine. Most available evidence comes from case reports, small case series, and database studies rather than large prospective trials 6, 7. The absolute risks remain uncertain due to potential confounding by the underlying psychiatric illness.

Dosing Considerations

Pregnancy dramatically reduces aripiprazole plasma concentrations—by 60.9% in the third trimester due to physiological changes 8. Women may require dose increases (approximately 2-fold) in late pregnancy to maintain therapeutic levels, though this must be balanced against neonatal risks.

Clinical Decision Algorithm

For Fluoxetine:

1. If currently stable on fluoxetine: Continue treatment, especially if history of severe depression or previous relapse with discontinuation
2. Monitor closely in third trimester for signs of premature labor and prepare neonatal team for possible poor adaptation syndrome
3. Do not switch medications solely due to pregnancy if patient is responding well

For Aripiprazole:

1. Assess severity of psychiatric illness: Schizophrenia and bipolar disorder carry substantial maternal and fetal risks when untreated (increased relapse, hospitalization, preterm birth) 4
2. If severe illness requiring antipsychotic: Aripiprazole is a reasonable option given its relatively favorable metabolic profile, though data are limited 6
3. Monitor for:
   • Pregnancy hypertension
   • Fetal growth parameters
   • Therapeutic drug levels (may need dose adjustment)
4. Prepare neonatal team for potential extrapyramidal/withdrawal symptoms requiring monitoring and possible prolonged hospitalization 4

Critical Caveats

• The underlying psychiatric illness itself poses risks: Untreated schizophrenia and severe depression are associated with adverse pregnancy outcomes independent of medication 3, 4
• Neonatal monitoring is essential for both medications, particularly with third-trimester exposure
• Abrupt discontinuation is dangerous: Never stop antidepressants or antipsychotics suddenly without medical supervision 4
• Individual risk-benefit discussion required: Consider severity of illness, previous treatment response, and patient preferences 3

The decision to use these medications should prioritize maternal mental health stability, as severe untreated psychiatric illness poses substantial risks to both mother and fetus that often exceed the medication-related risks 3, 4.